EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $24 at H.C. Wainwright

EyePoint Pharmaceuticals (EYPT) Prices 4.03M Share Offering at $13.75/sh

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten public offering of 4,027,273 shares of its common stock at a public offering price of $13.75 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at a price to the public of $13.74 per each pre-funded warrant, which represents the per share public offering price for the common... More

EyePoint Pharmaceuticals (EYPT) Announces $100M Stock Offering

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $15.0 million of shares of its common stock.

Cowen and Guggenheim Securities are acting as joint book-running managers for the offering. The offering is subject... More

EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $35 at Cowen

Cowen analyst Ken Cacciatore raised the price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to $35.00 (from $25.00) while maintaining an Outperform rating.

The analyst commented, "EYP-1901 6-month Phase I wet AMD results demonstrated excellent safety & potential best-in-class efficacy with 73% of patients rescue-free at month 4,... More

EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $31 at Cantor Fitzgerald

Cantor Fitzgerald analyst Jennifer Kim raised the price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) to $31.00 (from $22.00) while maintaining an Overweight rating.

The analyst commented, "Following presentation of the Ph1 DAVIO data for EYP-1901 the company's lead pipeline asset in wet age-related macular... More

EyePoint Pharmaceuticals (EYPT) Climbs 55% After Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Trial of EYP-1901

EyePoint Pharmaceuticals (NASDAQ: EYPT) Climbs 55% After Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Trial of EYP-1901